安进Amgen（AMGN）2025年第四季度及全年业绩报告「NASDAQ」（英文版）（28页）.pdf

1、News ReleaseOne Amgen Center DriveThousand Oaks,CA 91320-1799Telephone 805-447-AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTSTHOUSAND OAKS,Calif.(Feb.3,2026)-Amgen(NASDAQ:AMGN)today announced financial results for the fourth quarter and full year of 2025 versus the comparable peri

2、ods in 2024.Amgen delivered strong performance in 2025,with double-digit growth in revenues and earnings per share.We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth,said Robert A.Bradway,cha

3、irman and chief executive officer.Key results include:For the fourth quarter,total revenues increased 9%to$9.9 billion in comparison to thefourth quarter of 2024.Product sales grew 7%,driven by 10%volume growth,partially offset by 4%lower netselling price.For the full year,total revenues increased 1

4、0%to$36.8 billion in comparison to the full yearof 2024.Product sales grew 10%,driven by 13%volume growth,partially offset by 3%lower netselling price.Eighteen products achieved record sales for the full year.Fourteen products exceeded one billion dollars in annual sales.Thirteen products delivered

5、at least double-digit sales growth for the full year.GAAP earnings per share(EPS)increased 111%from$1.16 to$2.45 for the fourth quarter,driven by higher revenues and lower net unrealized losses on equity investments,partiallyoffset by higher operating expenses.For the full year,GAAP EPS increased 88

6、%from$7.56to$14.23,driven by higher revenues and net unrealized gains on our BeOne MedicinesLtd.(BeOne)equity investment,partially offset by higher operating expenses,includingOtezla(apremilast)intangible asset impairment charges of$1.2billion recorded in 2025,following the selection of Otezla for M